# Post Authorization Safety Study Moderna COVID-19 Primary Vaccine

> **NCT06006858** · — · COMPLETED · sponsor: **PT Bio Farma** · enrollment: 1284 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** Moderna COVID-19 Vaccine

## Key facts

- **NCT ID:** NCT06006858
- **Lead sponsor:** PT Bio Farma
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-03
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-03-31
- **Target enrollment:** 1284 (ACTUAL)
- **Last updated:** 2023-11-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06006858

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06006858, "Post Authorization Safety Study Moderna COVID-19 Primary Vaccine". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06006858. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*